Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: Properties, clinical development and applications

European Radiology

Volumn 14, Issue 4, 2004, Pages 559-578

  Reimer, Peter ^a   Schneider, Günter ^b   Schima, Wolfgang ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Characterisation; Classification; Detection; Dynamic MRI; Gadobenate dimeglumine; Gd EOB DTPA; Liver; Mangafodipir trisodium

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBENIC ACID; GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOXETIC ACID; MANGAFODIPIR; SH L 569 B; UNCLASSIFIED DRUG;

AKATHISIA; ANXIETY DISORDER; BILIARY EXCRETION; CELL SPECIFICITY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG MECHANISM; DRUG METABOLISM; DRUG PREFERENCE; DRUG SYNTHESIS; DRUG UPTAKE; DRUG USE; FLUSHING; HEADACHE; HUMAN; HYPERTENSION; IMAGE ANALYSIS; INJECTION SITE; INTERMETHOD COMPARISON; LIVER; LIVER CELL; LIVER DISEASE; MEDICAL DECISION MAKING; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PARESTHESIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TACHYCARDIA; TASTE DISORDER; THREE DIMENSIONAL IMAGING; VASODILATATION; VERTIGO;

CONTRAST MEDIA; EDETIC ACID; GADOLINIUM; GADOLINIUM DTPA; HUMANS; LIVER; LIVER DISEASES; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MANGANESE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PYRIDOXAL PHOSPHATE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 1842450733     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-004-2236-1     Document Type: Review

References (86)

1. Bellin MF, Vasile M, Morel-Precetti S (2003) Currently used non-specific extracellular MR contrast media. Eur Radiol 13:2688-2698
2. Brasch RC (1992) New directions in the development of MR imaging contrast media. Radiology 183:1-11
3. Reimer P, Balzer T (2003) Ferucarbotran (Resovist): A new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: Properties, clinical development, and applications. Eur Radiol 13:1266-1276
4. Reimer P, Tombach B (1998) Hepatic MRI with SPIO: Detection and characterization of focal liver lesions. Eur Radiol 8:1198-1204
5. Wang YX, Hussain SM, Krestin GP (2001) Superparamagnetic iron oxide contrast agents: Physicochemical characteristics and applications in MR imaging. Eur Radiol 11:2319-2331
6. Schneider G et al (2001) Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: Effect of dose on lesion detection and delineation. J Magn Reson Imaging 14:525-539
7. Schima W et al (1997) Contrast-enhanced MR imaging of the liver: Comparison between Gd-BOPTA and Mangafodipir. J Magn Reson Imaging 7:130-135
8. Petersein J et al (2000) Focal liver lesions: Evaluation of the efficacy of gadobenate dimeglumine in MR imaging - a multicenter phase III clinical study. Radiology 215:727-736
9. Bernardino ME et al (1992) Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity. Radiology 183:53-58
10. Rofsky NM et al (1993) Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging. Radiology 188:53-59
11. Ni Y et al (1994) MR imaging evaluation of liver enhancement by Gd-EOB-DTPA in selective and total bile duct obstruction in rats: correlation with serologic, microcholangiographic, and histologic findings. Radiology 190:753-758
12. Marchal G et al (1993) Comparison between Gd-DTPA, Gd-EOB-DTPA, and Mn-DPDP in induced HCC in rats: A correlation study of MR imaging, microangiography, and histology. Magn Reson Imaging 11:665-674
13. Toft K et al (1997) Metabolism and pharmacokinetics of MnDPDP in man. Acta Radiol 38:677-689
14. Elizondo G et al (1991) Preclinical evaluation of Mn-DPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 178:73-78
15. Misselwitz B, Mühler A, Weinmann H-J (1995) A toxicologic risk for using manganese complexes? A literature survey of existing data through several medical specialties. Invest Radiol 30:611-620
16. Lim KO et al (1991) Hepatobiliary MR imaging: First human experience with Mn-DPDP. Radiology 178:79-82
17. Wang C et al (1997) Diagnostic efficacy of MnDPDP in MR imaging of the liver. Acta Radiol 38:643-649
18. Padovani B et al (1996) Tolerability and utility of mangafodipir trisodium injection (MnDPDP) at the dose of 5 μmol/kg body weight in detecting focal liver tumors: Results of a phase III trial using an infusion technique. Eur J Radiol 23:205-211
19. Bernhard C et al (2002) Safety of mangafodipir administration at abdominal MR imaging: Bolus injection vs. slow infusion. Eur Radiol 12 [Suppl 1]:291
20. Rummeny E et al (1991) Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumors. Results of clinical phase 2 trials in Germany including 141 patients. Invest Radiol 26: S142-S145
21. Watson A (1992) Theory and mechanisms of contrast-enhancing agents. In: CB H, H H, CA H (eds) Magnetic resonance imaging of the body. Raven Press, New York
22. de Haen C, Lorusso V, Tirone P (1996) Hepatic transport of gadobenate dimeglumine in TR-rats. Acad Radiol 3 [Suppl 2]:S452-S454
23. Kirchin MA, Pirovano GP, Spinazzi A (1998) Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 33:798-809
24. Spinazzi A et al (1999) Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 6:282-291
25. de Haen C, Gozzini L (1993) Soluble-type hepatobiliary contrast agents for MR imaging. J Magn Reson Imaging 3:179-186
26. de Haen C, La Ferla R, Maggioni F (1999) Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) as contrast agent for magnetic resonance imaging of the liver: Mechanistic studies in animals. J Comput Assist Tomogr 23 [Suppl 1]:S169-S179
27. Cavagna FM et al (1997) Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 32:780-796
28. Schuhmann-Giampieri G (1993) Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging. Invest Radiol 28:753-761
29. Spinazzi A et al (1998) Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 5 [Suppl 1]:S86-S89 (discussion S93-S94)
30. Kirchin MA et al (2001) Safety assessment of gadobenate dimeglumine (MultiHance): Extended clinical experience from phase I studies to post-marketing surveillance. J Magn Reson Imaging 14:281-294
31. Weinmann HJ et al (1991) A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 22:233-237 (discussion 242)
32. Schuhmann-Giampieri G et al (1992) Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 183:59-64
33. Muehler A et al (1993) Gadolinium-ethoxybenzyl-DTPA, a new liver-directed magnetic resonance contrast agent. Absence of acute hepatotoxic, cardiovascular, or immunogenic effects. Invest Radiol 28:26-32
34. Hamm B et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: Safety, pharmacokinetics, and MR imaging. Radiology 195:785-792
35. Reimer P et al (1996) Phase II clinical evaluation of Gd-EOB-DTPA: Dose, safety aspects, and pulse sequence. Radiology 199:177-183
36. Shamsi K et al (2002) Gd-EOB-DTPA (Eovist), a liver specific contrast agent for MRI: Results of a placebo controlled, double blind dose ranging study in patients with focal liver lesions. Tenth scientific meeting and exhibition of the International Society for Magnetic Resonance in Medicine. ISMRM, Honolulu, HI, USA
37. Huppertz A et al (2004) Improved detection of focal liver lesions in MRI - a multicenter comparison of Gd-EOB-DTPA with intraoperative findings. Radiology 230:266-275
38. Aicher KP et al (1993) Mn-DPDP-enhanced MR imaging of malignant liver lesions: Efficacy and safety in 20 patients. J Magn Reson Imaging 3:731-737
39. Gehl H-B et al (1991) Pancreatic enhancement after low-dose infusion of Mn-DPDP. Radiology 180:337-339
40. Gehl H-B et al (1993) Mn-DPDP in MR imaging of pancreatic adenocarcinoma: Initial clinical experience. Radiology 186:795-798
41. Romijn MG et al (2000) MRI with mangafodipir trisodium in the detection and staging of pancreatic cancer. J Magn Reson Imaging 12:261-268
42. Schima W, Függer R (2002) Evaluation of focal pancreatic masses: Comparison of mangafodipir-enhanced MR imaging and contrast-enhanced helical CT. Eur Radiol 12:2998-3008
43. King LJ et al (2002) MnDPDP enhanced magnetic resonance imaging of focal liver lesions. Clin Radiol 57:1047-1057
44. Federle MP et al (2000) Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the US multicenter phase III clinical trials. Efficacy of early imaging. J Magn Reson Imaging 12:689-701
45. Braga HJ et al (2002) Liver lesions: Manganese-enhanced MR and dual-phase helical CT for preoperative detection and characterization comparison with receiver operating characteristic analysis. Radiology 223:525-531
46. Mann GN et al (2001) Clinical and cost effectiveness of a new hepatocellular MRI contrast agent, mangafodipir trisodium, in the preoperative assessment of liver resectability. Ann Surg Oncol 8:573-579
47. Hamm B et al (1992) Focal liver lesions: MR imaging with Mn-DPDP - initial clinical results in 40 patients. Radiology 182:167-174
48. Mathieu D et al (1999) Unexpected MR-T1 enhancement of endocrine liver metastases with mangafodipir. J Magn Reson Imaging 10:193-195
49. Marti-Bonmati L et al (1998) MnDPDP enhancement characteristics and differentiation between cirrhotic and noncirrhotic livers. Invest Radiol 33:717-722
50. Murakami T et al (1996) Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP). Radiology 198:567-572
51. Vogl TJ et al (1993) Mn-DPDP enhancement patterns of hepatocellular lesions on MR images. J Magn Reson Imaging 3:51-58
52. Liou J et al (1994) Differentiation of hepatomas from nonhepatomatous masses: Use of Mn-DPDP-enhanced MR images. Magn Reson Imaging 12:71-79
53. Murakami T et al (1996) Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP). Radiology 200:69-77
54. Bartolozzi C et al (2000) MnDPDP-enhanced MRI vs dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis. Eur Radiol 10:1697-1702
55. Kim SK et al (2002) Preoperative detection of hepatocellular carcinoma: Ferumoxides-enhanced versus mangafodipir trisodium-enhanced MR imaging. AJR 179:741-750
56. Ba-Ssalamah A et al (2002) Atypical focal nodular hyperplasia of the liver: Imaging features of nonspecific and liver-specific MR contrast agents. AJR 179:1447-1456
57. Oudkerk M et al (2002) Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: Multicenter study comparing MR and dual-phase spiral CT. Radiology 223:517-524
58. Coffin CM et al (1999) Benign and malignant hepatocellular tumors: Evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging. Eur Radiol 9:444-449
59. Helmberger TK et al (2002) MRI characteristics in focal hepatic disease before and after administration of MnDPDP: Discriminant analysis as a diagnostic tool. Eur Radiol 12:62-70
60. Saini S (1992) Contrast-enhanced MR imaging of the liver. Radiology 182:12-14
61. Hamm B, Taupitz M (1995) Use of contrast agents in the detection and differentiation of focal liver lesions by MR imaging: Gd-DTPA, Mn-DPDP and iron oxide. In: Balzer T, Hamm B, Niendorf H-P (eds) Contrast agents in liver imaging. Kluwer, Dordrecht
62. Nakamura H et al (1994) 3DFT-FISP MRI with gadopentetate dimeglumine in differential diagnosis of small liver tumors. J Comput Assist Tomogr 18:49-54
63. Powers C et al (1994) Primary liver neoplasms: MR imaging with pathologic correlation. Radiographics 14:459-482
64. Mahfouz AE, Hamm B, Wolf KJ (1994) Peripheral washout: A sign of malignancy on dynamic gadolinium-enhanced MR images of focal liver lesions. Radiology 190:49-52
65. Semelka RC et al (1994) Hepatic hemangiomas: A multi-institutional study of appearance on T2-weighted and serial gadolinium-enhanced gradient-echo MR images. Radiology 192:401-406
66. Hamm B et al (1994) Focal liver lesions: Characterization with nonenhanced and dynamic contrast material-enhanced MR imaging. Radiology 190:417-423
67. Hamm B et al (1997) Liver metastases: Improved detection with dynamic gadolinium-enhanced MR imaging? Radiology 202:677-682
68. Cavagna FM et al (1990) Hepatobiliary contrast agents for MRI. In: Ferrucci J, Stark D (eds) Civer imaging: current trends and new techniques. Andover Medical Publishers Inc., Boston
69. Kuwatsuru R et al (2001) Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors. Invest Radiol 36):632-641
70. Schneider G et al (2003) Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: An intra-individual crossover comparison. Invest Radiol 38:85-94
71. Morana G et al (2002) Hypervascular hepatic lesions: Dynamic and late enhancement pattern with Gd-BOPTA. Acad Radiol 9 [Suppl 2]:476-479
72. Grazioli L et al (2003) MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): An intra-individual comparison. J Magn Reson Imaging 17:593-602
73. Reimer P et al (1997) Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol 7:275-280
74. Stern W et al (2000) Dynamic MR imaging of liver metastases with Gd-EOB-DTPA. Acta Radiol 41:255-262
75. Vogl T et al (1995) Enhancement of malignant and benign focal liver lesions using Gd-EOB-DTPA and Gd-DTPA enhanced MRI in the same patient. In: International conference of MRI of the abdomen and pelvis. H.M. Hauschild Ltd, Bremen, Munich, Germany
76. Kuehnen J, Schering AG (2003) Results of European Phase 3 Clinical trials on Gd-EOB-DTPA. Personal communication, Berlin, Germany
77. Kane PA et al (1997) MnDPDP-enhanced MR imaging of the liver. Correlation with surgical findings. Acta Radiol 38:650-654
78. Petersein J et al (2000) Comparison of in-phase and out-of-phase gradient recalled echo T1-weighted pulse sequences for MR imaging of malignant liver masses following administration of paramagnetic gadolinium-chelate. Abdom Imaging 25:159-163
79. Bollow M et al (1997) Gadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: Results of an in vivo phase-I clinical evaluation. Eur Radiol 7:126-132
80. Hirohashi S et al (1998) Optimal dose of hepatobiliary contrast agent for MR cholangiography: Experimental study in rats. J Magn Reson Imaging 8:847-852
81. Schmitz SA et al (1996) Functional hepatobiliary imaging with gadolinium-EOB-DTPA. A comparison of magnetic resonance imaging and 153 gadolinium-EOB-DTPA scintigraphy in rats. Invest Radiol 31:154-160
82. Schuhmann-Giampieri G et al (1993) Biliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the rat. J Pharm Sci 82:799-803
83. Lee VS et al (2001) Volumetric mangafodipir trisodium-enhanced cholangiography to define intrahepatic biliary anatomy. AJR 176:906-908
84. Vitellas KM et al (2001) Detection of bile duct leaks using MR cholangiography with mangafodipir trisodium (Teslascan). J Comput Assist Tomogr 25:102-105
85. Vogl TJ et al (1996) Liver tumors: Comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 200:59-67
86. Hammerstingl R et al (2002) Contrast-enhanced MRI of focal liver tumors using a hepatobiliary MR contrast agent: Detection and differential diagnosis using Gd-EOB-DTPA-enhanced versus Gd-DTPA-enhanced MRI in the same patient. Acad Radiol 9 [Suppl 1]: S119-S120